To the Editor:
We read with great interest the article by Gottschalk et al
and wish to congratulate them for their great and remarkable work. They showed that, although the use of epidural analgesia for perioperative pain control during colorectal cancer surgery was not associated with a lower rate of cancer recurrence, a potential benefit was observed in older patients. Their results were in contrast with those of Christopherson et al.
whose study population was similar, apart from sample size.
Nevertheless, the primary endpoints of these two studies were different. Gottschalk et al.1
reported the incidence of cancer recurrence whereas Christopherson et al.2
found a difference in terms of survival.
However, the definition of cancer recurrence used by Gottschalk et al.1
would be of interest. The application of their findings may be limited as a result of this omission. Establishing a diagnosis for local recurrence can be particularly difficult in rectal cancer patients. It is for this reason that researchers3
often consider reported rates of recurrence in this population to be of limited value. In this study, readers are uncertain about study methodology, potential bias, and the incidence of cancer-related death in both groups (epidural vs
. nonepidural). Therefore, the results of Gottschalk et al.1
might best be considered inconclusive.
Moreover, epidural analgesia is not the only intraoperative variable that could influence cancer outcomes. In the study by Gottschalk et al.
the epidural group presented with more rectal cancer, higher histologic grade, more frequent radiotherapy and chemotherapy, and more blood loss, suggesting more difficult surgeries. All these characteristics are potential confounding factors that may impact the rate of cancer recurrence. Even if multivariate analysis has been well performed, these patients' characteristics increases the risk that the epidural group includes other unknown negative factors. In addition, Gottschalk et al.
do not make available data concerning the number of nodes removed or the quality of the mesorectum—both indicators of surgery quality.
Finally, another potential bias in this study is the intraoperative use of nonsteroidal antiinflammatory drugs. The overexpression of cyclooxygenase type 2 and the possible immunoprotective effect of these drugs may have an impact on long-term cancer recurrence.4
It would be of interest to know if the groups are balanced for the use of these medications. Indeed, the older patients are often more prone to not receive nonsteroidal anti-inflammatory drugs. And the effect of the epidural analgesia might then have been unmasked for this reason. Following this hypothesis, in younger patients, these drugs may have masked the effect of epidural analgesia.
In conclusion, interpretation of the results reported by Gottschalk et al.1
must wait until their methodology is further clarified.
Patrice Forget, M.D.,*
Daniel Leonard, M.D.
Alex Kartheuser, M.D., M.Sc., Ph.D.
Marc De Kock, M.D., Ph.D.
* Université catholique de Louvain, Steet-Luc University Hospital, Brussels, Belgium. email@example.com
1.Gottschalk A, Ford JG, Regelin CC, You J, Mascha EJ, Sessler DI, Durieux ME, Nemergut EC: Association between epidural analgesia and cancer recurrence after colorectal cancer surgery. Anesthesiology 2010; 113:27–34
2.Christopherson R, James KE, Tableman M, Marshall P, Johnson FE: Long-term survival after colon cancer surgery: A variation associated with choice of anesthesia. Anesth Analg 2008; 107:325–32
3.Dent OF, Chapuis PH, Bokey EL, Newland RC: Methodology and reporting in studies of local recurrence after curative excision of the rectum for cancer. Br J Surg 2001; 88:1476–80
4.Wang D, Dubois RN: The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene 2010; 29:781–8
© 2011 American Society of Anesthesiologists, Inc.